melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
About Us
Our Services
HIGH THROUGHPUT IN VIVO PHARMACOLOGY:
DISCOVERY SERVICES:
Our Technology
Partnering with Us
Press & Publications
Contact Us
melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Our Services indications discovery


theraTRACE®
Melior Discovery Inc (Exton, PA, USA) has pioneered a unique “high throughput” in vivo pharmacology platform (theraTRACE®) able to systematically identify novel indications for pre-clinical and development stage drugs. theraTRACE® is widely used by both multinational pharmaceutical and start-up biopharmaceutical companies alike to fully explore the therapeutic potential of their drug candidates.

Click here for a comprehensive list of major therapeutic areas and specific models

Melior has also leveraged this expertise to build a high quality, onshore and cost-effective preclinical services capability offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models and bioanalytical services to drug developers worldwide.


Uniquely Productive Drug Discovery Strategy

The theraTRACE® indications discovery platform allows for known drug-like compounds to be comprehensively screened using a battery of in vivo assays spanning multiple therapeutic areas. Currently over 40 validated animal models are represented in the platform spanning a broad range of therapeutic areas including inflammation, immunology, diabetes & metabolic syndrome, dermatology, cardiovascular, gastrointestinal, psychiatric, neurological and neurodegenerative disorders. The in vivo models utilized in the theraTRACE® platform comprise those typically used by pharmaceutical companies to determine whether a drug candidate is suitable for further clinical evaluation, however, these models are assembled in a proprietary “multiplexed” format that allows drug discoverers to evaluate a compound for potential efficacy in a broad array of therapeutic areas rapidly and cost-effectively. In most cases, Melior’s theraTRACE® system is able to provide a complete pharmacological fingerprint/profile of a compound in 10 weeks. Melior’s theraTRACE® system has found particular utility in facilitating the crucial “go/no go” development decisions routinely faced by pharmaceutical and biopharmaceutical companies.

Back to top of page
 
home